Quote | Bright Minds Biosciences Inc Com (OTCMKTS:BMBIF)
Last: | $7.98 |
---|---|
Change Percent: | -1.85% |
Open: | $8.52 |
Close: | $7.98 |
High: | $8.52 |
Low: | $7.75 |
Volume: | 61,753 |
Last Trade Date Time: | 11/05/2021 04:54:29 pm |
News | Bright Minds Biosciences Inc Com (OTCMKTS:BMBIF)
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascend...
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascendin...
Message Board Posts | Bright Minds Biosciences Inc Com (OTCMKTS:BMBIF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc Com Company Name:
BMBIF Stock Symbol:
OTCMKTS Market:
Bright Minds Biosciences Inc Com Website:
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascend...
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascendin...
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatr...